FINWIRES · TerminalLIVE
FINWIRES

Top Cryptocurrencies Mixed; Bitcoin Drops Below $75,000

By

Top cryptocurrencies were mixed on Wednesday, with Bitcoin (BTC-USD) falling below the $75,000 level.

The CoinDesk Market Index, which tracks dozens of digital assets including Bitcoin, fell 0.3% in the past 24 hours. The Nasdaq 100 fell 0.1%, the S&P 500 added 0.1%, and the Dow Jones Industrial Average rose 0.4%.

Bitcoin fell 1.2% to $74,895, according to CoinMarketCap data. The most popular cryptocurrency's 24-hour trading volume fell 8.9% to $31.96 billion.

Ethereum (ETH-USD), the second-largest digital asset by market value, fell 0.7% to $2,055.

XRP (XRP-USD) rose 0.1%, BNB (BNB-USD) shed 0.4%, and Solana (SOL-USD) gained 0.4%. Dogecoin (DOGE-USD) rose 1.2%, and Cardano (ADA-USD) gained 0.7%.

The US 10-year Treasury yield stood at 4.477% at 3 p.m. ET Wednesday, down from 4.491% Tuesday, while the five-year yield fell to 4.172% from 4.183%.

The total market value of the cryptocurrency industry fell 0.8% in the past 24 hours to $2.52 trillion, with trading volume declining 9.2% to $84.47 billion.

Price: $74893.08, Change: $-936.33, Percent Change: -1.23%

Related Articles

Wire

Ooma Fiscal Q1 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Ooma (OOMA) reported fiscal Q1 adjusted earnings late Tuesday of $0.35 per diluted share, up from $0.20 a year earlier.Analysts polled by FactSet expected $0.32.Revenue in the three months ended April 30 rose to $81.1 million from $65 million a year earlier.Analysts surveyed by FactSet expected $79.8 million.Ooma expects fiscal Q2 adjusted EPS of $0.33 to $0.34 on revenue of $81.6 million to $82.3 million.Analysts polled by FactSet expect EPS of $0.31 on revenue of $80.2 million.The company boosted fiscal 2027 adjusted EPS guidance to $1.29 to $1.34 on revenue of $326 million to $328.5 million. Prior guidance was EPS of $1.26 to $1.31 on revenue of $321 million to $325 million.Analysts surveyed by FactSet expect EPS of $1.29 on revenue of $322.8 million.Ooma shares rose 4.8% in after-hours trading.

$OOMA
Wire

Jade Biosciences Says First Participant Dosed in First-in-Human Phase 1 Trial of JADE201

Jade Biosciences (JBIO) said late Tuesday the first participant has been dosed in a first-in-human phase 1 clinical trial of JADE201, an investigational, half-life extended, afucosylated monoclonal antibody.The first-in-human trial is a placebo-controlled study assessing single ascending doses of JADE201 in participants with rheumatoid arthritis, according to a statement.Jade said interim phase 1 data in rheumatoid arthritis anticipated in 2027 are expected to inform indication prioritization across potential autoimmune indications supported by B cell activating factor receptor biology.

$JBIO
Wire

Zscaler Fiscal Q3 Adjusted Earnings, Revenue Rise; Q4 Guidance Set

Zscaler (ZS) reported fiscal Q3 adjusted earnings late Tuesday of $1.08 per diluted share, up from $0.84 a year earlier.Analysts polled by FactSet expected $1.01.Revenue for the three months ended April 30 was $850.5 million, up from $678 million a year earlier.Analysts surveyed by FactSet expected $835.6 million.For fiscal Q4, the company expects adjusted EPS of $1.08 to $1.09 on revenue of $875 million to $878 million. Analysts expect EPS of $1.03 on revenue of $878.6 million.For the full-year fiscal 2026, the company now expects adjusted EPS of $4.10 to $4.11 on revenue of $3.329 billion to $3.332 billion. It earlier expected adjusted EPS of $3.99 to $4.02 on revenue of $3.31 billion to $3.32 billion.Analysts expect EPS of $4.01 on revenue of $3.32 billion.

$ZS